Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/22/2024 | $81.00 → $92.00 | Neutral → Outperform | Robert W. Baird |
| 2/26/2024 | $78.00 | Market Perform | Leerink Partners |
| 12/12/2023 | $71.00 → $82.00 | Neutral → Overweight | JP Morgan |
| 11/10/2023 | $70.00 | Hold → Buy | Stifel |
| 8/8/2022 | $80.00 | Sell → Neutral | UBS |
| 7/21/2022 | $93.00 → $85.00 | Buy → Neutral | Goldman |
| 6/14/2022 | $103.00 → $88.00 | Outperform → Neutral | Robert W. Baird |
| 5/13/2022 | $100.00 | Outperform | Credit Suisse |
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conferences in December: Piper Sandler's Healthcare Conference at Lotte New York Palace Hotel, New York, on December 4, 2024, at 11:00 a.m. Eastern time. Evercore ISI HealthCONx Conference at Loews Coral Gables Hotel, Coral Gables, Florida, on December 5, 2024, at 9:10 a.m. Eastern time. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations. Abo
Acquisition will Enhance Home Delivery Options for Patients with Specialized Health Care Needs Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it has signed an agreement to acquire Acentus, a national medical supplier specializing in the delivery of Continuous Glucose Monitors (CGMs). The Acentus transaction follows Henry Schein's acquisition of Prism Medical Products, LLC in 2021 and Shield Healthcare and Mini Pharmacy in 2023, reinforcing the Company's strategic commitment to the homecare medical supplies market. Henry Schein's homecare medical products platform will now have
Third-quarter 2024 GAAP diluted EPS of $0.78 and non-GAAP diluted EPS of $1.22 Operating cash flow of $151 million for the third quarter of 2024; year-to-date operating cash flow of $644 million, up $112 million compared with year-to-date 2023 Increases 2024 full-year non-GAAP EPS guidance to $4.74 to $4.82 from $4.70 to $4.82 Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the third quarter ended September 28, 2024. "Our businesses performed well during the third quarter, driven by the continued successful implementation of our BOLD+1 Strategic Plan that is
SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)
SC 13G - HENRY SCHEIN INC (0001000228) (Subject)
SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)
4 - HENRY SCHEIN INC (0001000228) (Issuer)
4 - HENRY SCHEIN INC (0001000228) (Issuer)
4/A - HENRY SCHEIN INC (0001000228) (Issuer)
Robert W. Baird upgraded Henry Schein from Neutral to Outperform and set a new price target of $92.00 from $81.00 previously
Leerink Partners initiated coverage of Henry Schein with a rating of Market Perform and set a new price target of $78.00
JP Morgan upgraded Henry Schein from Neutral to Overweight and set a new price target of $82.00 from $71.00 previously
Third-quarter 2024 GAAP diluted EPS of $0.78 and non-GAAP diluted EPS of $1.22 Operating cash flow of $151 million for the third quarter of 2024; year-to-date operating cash flow of $644 million, up $112 million compared with year-to-date 2023 Increases 2024 full-year non-GAAP EPS guidance to $4.74 to $4.82 from $4.70 to $4.82 Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the third quarter ended September 28, 2024. "Our businesses performed well during the third quarter, driven by the continued successful implementation of our BOLD+1 Strategic Plan that is
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its third quarter 2024 financial results before the stock market opens on Tuesday, November 5, 2024, and will provide a live webcast of its earnings conference call on the same day beginning at 10:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be availabl
Highlights: Second-quarter 2024 GAAP diluted EPS of $0.80, and non-GAAP diluted EPS of $1.23 Operating cash flow of $296 million for the second quarter of 2024, year-to-date operating cash flow of $493 million up $192 million compared with year-to-date 2023 2024 full-year non-GAAP EPS guidance updated to $4.70 to $4.82 New restructuring plan targeting $75 million to $100 million in annual run-rate savings Share repurchase authorization increased by $500 million Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June 29, 2024.
Joining Henry Schein's EMC are Steve Boggan and Bianka Wilson, Co-CEOs of the Global Oral Reconstruction Group, and Tom Popeck, CEO of the Healthcare Specialties Group Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, today announced that it has appointed three new members to the Company's Executive Management Committee (EMC) – Steve Boggan and Bianka Wilson, who were recently named Co-CEOs of the Company's Global Oral Reconstruction Group (GORG), and Tom Popeck, CEO of the Company's Healthcare Specialties Group (HSG). This press release features multimedia. View the full release here: https://www.busi
Applications for the Second Annual 2024 S.M.I.L.E. Healthcare Pathway Program are now being accepted Henry Schein, Inc. (NASDAQ:HSIC), National Dental Association (NDA), and Schattner Foundation are pleased to partner and present the S.M.I.L.E. (Student Mentoring with Immersive Learning and Enrichment) Healthcare Pathway Program. This innovative public-private partnership is designed to mentor and support aspiring healthcare professionals and enhance inclusivity within the dental field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240220083937/en/ Applications are now being accepted for the 2024 program taking place July 7 t
WASHINGTON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The American Dental Association Foundation's Give Kids A Smile® (GKAS) program, one of the largest national initiatives focused on children and dental care, is kicking off at Howard University College of Dentistry on Thursday, Feb. 1 and Friday, Feb. 2, 2024. The American Dental Association (ADA) launched Give Kids A Smile 22 years ago as a way for dentists across the country to join with others in the community to provide free dental services to underserved children while also highlighting for policy makers the ongoing challenges that underserved families face in finding and affording dental care. The national Give Kids A Smile kick-of
10-Q - HENRY SCHEIN INC (0001000228) (Filer)
8-K - HENRY SCHEIN INC (0001000228) (Filer)
10-Q - HENRY SCHEIN INC (0001000228) (Filer)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs cut the price target for Lennar Corporation (NYSE:LEN) from $180 to $174. Goldman Sachs analyst Susan Maklari downgraded the stock from Buy to Neutral. Lennar shares gained 0.5% to close at $170.94 on Friday. See how other analysts view this stock. Piper Sandler increased the price target for NVIDIA Corporation (NASDAQ:NVDA) from $120 to $140. Piper Sandler analyst Harsh Kumar maintained an Overweight rating. NVIDIA shares fell 2.6% to close at $117.93 on Friday. See how other analyst
In the preceding three months, 6 analysts have released ratings for Henry Schein (NASDAQ:HSIC), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 2 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 1 0 0 2M Ago 0 1 0 0 0 3M Ago 0 1 1 0 0 In the assessment of 12-month price targets, analysts unveil insights for Henry Schein, presenting an average target of $85.67, a high estimate of $92.00, and a low estimate of $72.00. Observing a
Baird analyst Jeff Johnson upgrades Henry Schein (NASDAQ:HSIC) from Neutral to Outperform and raises the price target from $81 to $92.